iShares US Pharmaceuticals ETF
143 hedge funds and large institutions have $374M invested in iShares US Pharmaceuticals ETF in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 45 increasing their positions, 44 reducing their positions, and 14 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 44
0% more funds holding
Funds holding: 143 → 143 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
0.16% less ownership
Funds ownership: 56.82% → 56.66% (-0.16%)
3% less capital invested
Capital invested by funds: $387M → $374M (-$12.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.47M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.72M |
| 3 |
RW
Rockport Wealth
Fairview Park,
Ohio
|
+$1.63M |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$828K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$581K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSCM
McElhenny Sheffield Capital Management
Dallas,
Texas
|
-$18.9M |
| 2 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
-$12.8M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$6.18M |
| 4 |
RCM
Raleigh Capital Management
Cary,
North Carolina
|
-$1.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.31M |
IHE Hedge Fund Activity: Q3 2024 in Review
143 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2024, worth a combined $374M — down 3.3% from $387M a quarter earlier.
Fund positioning in IHE was balanced in Q3 2024: 14 funds opened new positions, 14 closed out, 45 added to existing stakes and 44 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $3.47M. The largest seller was McElhenny Sheffield Capital Management, exiting entirely with an estimated $18.9M sold.
- 143 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $374M of iShares US Pharmaceuticals ETF stock for Q3 2024, down 3.3% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2024 and 14 closed out, a net change of 0 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2024 was Goldman Sachs, an estimated $3.47M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2024 was McElhenny Sheffield Capital Management, an estimated $18.9M sold.
Based on aggregated 13F filings for Q3 2024.